Biotechnology company Oxford BioDynamics, Plc (AIM: OBD) announced on Wednesday that clinical validation of its EpiSwitch Prostate Screening (PSE) test has been completed at its newly commissioned ISO15189 UK clinical laboratory. The move halves the turnaround time for PSE tests ordered by UK physicians, enhancing accessibility.
The PSE test, with 94% accuracy, combines PSA scores with proprietary epigenetic biomarkers to predict prostate cancer presence. The test aids in avoiding unnecessary biopsies for low-risk cases and prompts referrals for further investigation in high-risk instances.
OBD will soon validate its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) within the UK facility, targeting immuno-oncology checkpoint inhibitor treatments. This advance bolsters OBD's precision medicine offerings, positioning it as a key player in the global biotechnology landscape.
Headquartered in Oxford, UK, Oxford BioDynamics is listed on AIM of the London Stock Exchange. With a robust technology portfolio and numerous partnerships, OBD is at the forefront of developing personalised healthcare solutions based on its proprietary EpiSwitch platform.
Takeda's HYQVIA gains FDA approval for CIDP maintenance therapy
ANGLE signs USD250,000 contract with Eisai for HER2 assay pilot study
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus